La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Immunocore Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Immunocore Hldgs..

Immunocore Hldgs (NASDAQ:IMCR) Azioni, Catena delle Opzioni

Immunocore Hldgs

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings PLC

Seaport Global analyst Tom Curran initiates coverage on First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Neutral rating.

News

Initiation

Analyst Ratings

FSLR

Seaport Global Initiates Coverage On First Solar with Neutral Rating

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $480 to $486.

Price Target

VRTX

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $486

Scotiabank analyst Greg Harrison maintains Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Sector Outperform and raises the price target from $62 to $70.

IRON

Scotiabank Maintains Sector Outperform on Disc Medicine, Raises Price Target to $70

Scotiabank analyst Mario Saric maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $55.5 to $59.5.

Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $59.5

Scotiabank analyst Andres Coello maintains TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) with a Sector Outperform and lowers the price target from $24.8 to $23.2.

TIMB

Scotiabank Maintains Sector Outperform on TIM, Lowers Price Target to $23.2

Scotiabank analyst Maher Yaghi maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$50.5 to C$47.5.

TSX:BCE

Scotiabank Maintains Sector Perform on BCE, Lowers Price Target to C$47.5

Citigroup analyst Christopher Danely maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $40.

Citigroup Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $40

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) passed Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to become the world's largest publicly traded <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">company on Tuesday. </a>
The Details: Nvidia ended Tuesday's trading session with a market capitalization of $3.43 trillion, slightly <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">edging out </a>Apple&#8217;s $3.38 trillion valuation, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. The semiconductor giant's dominance in the artificial intelligence chip market has fueled its exponential growth of more than 200% over the past year.&nbsp;
Read More: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Nvidia briefly passed Apple <a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world">in market cap </a>in June before sliding over the summer.<a href="https://www.cnbc.com/quotes/MSFT/"> </a>Nvidia&#8217;s ascent to the top highlights the growing importance of AI technology and the pivotal role that Nvidia's specialized hardware plays in its development.&nbsp;
Despite Nvidia's remarkable growth over the past year, analysts remain bullish on the company's growth ahead. The three most recent analyst ratings were released by BofA Securities, Goldman Sachs and Morgan Stanley in October with an average price target of $163.33 between the three. There&#8217;s an implied 17.04% upside for Nvidia stock from these analyst ratings.
Last Friday, S&amp;P Dow Jones announced that Nvidia <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">is joining the Dow Jones Industrial Average on Nov. 8 </a>replacing Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and joining Apple in the blue-chip index. 
NVDA Price Action: According to data from Benzinga Pro, Nvidia shares ended Tuesday's session 2.84% higher at $139.91.&nbsp;
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690154/shock-october-jobs-report-leaves-fed-in-tight-spot-experts-say-interest-rate-cuts-a">Shock October Jobs Report Leaves Fed In &#8216;Tight Spot:&#8217; Experts Say Interest Rate Cuts Ahead</a></li>
</ul>
Image: Shutterstock

Large Cap

Movers

Tech

AAPL

INTC

NVDA

Nvidia Blows Past Apple To Become World's Most Valuable Company

Lake Street analyst Mark Argento maintains Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) with a Buy and raises the price target from $6 to $7.

GAIA

Lake Street Maintains Buy on Gaia, Raises Price Target to $7

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) with a Buy and raises the price target from $34 to $40.

CSTL

Lake Street Maintains Buy on Castle Biosciences, Raises Price Target to $40

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $60 to $41.

NSSC

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) .

Guidance

GIFI

Gulf Island Fabrication expect FY2024 adjusted consolidated EBITDA of $11M-$13M.

Lake Street analyst Eric Martinuzzi maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Hold and raises the price target from $20 to $25.

QNST

Lake Street Maintains Hold on QuinStreet, Raises Price Target to $25

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) .

SNDX

Syndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.

Loop Capital analyst Rob Sanderson maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Buy and raises the price target from $14 to $16.

SNAP

Loop Capital Maintains Buy on Snap, Raises Price Target to $16

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) .

GPOR

Gulfport Energy Full Year 2024: Drilling and completion capex guidance cut to $325M-$335M.

Loop Capital analyst Garik Shmois maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Buy and lowers the price target from $105 to $100.

Loop Capital Maintains Buy on Knife River Holding, Lowers Price Target to $100

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Politics

General

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

WIIM

WillScot Holdings shares are trading higher following a report suggesting activist investor TOMS has built a stake in the company and is pushing for a review.

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on IMCR stock, giving a Buy rating on September 9. Jonathan Chang has g...

Buy Rating Affirmed for Immunocore Holdings on Promising Brenetafusp Prospects and Strong Company Fundamentals

BlackRock Health Sciences Term Trust Q2 2024 Commentary

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Immunocore Holdings (IMCR – Research Report). The associated p...

Buy Rating Affirmed for Immunocore Holdings on Strong Therapeutic Prospects and Positive Clinical Data

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price tar...

TD Cowen Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Immunocore Holdings (IMCR – Research Report) today and set a price target of $1...

Buy Rating Affirmed for Immunocore Holdings on Strong Clinical Trial Results and Solid Financial Analysis

In a report released today, Gil Blum from Needham maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price target of $...

Buy Rating Affirmed for Immunocore Holdings Amid Promising Clinical Results and Strategic Expansion

Barclays analyst Peter Lawson assigned a Buy rating to Immunocore Holdings (IMCR – Research Report) today and set a price target of $66.00. The com...

Barclays Gives a Buy Rating to Immunocore Holdings (IMCR)

Capital One Financial analyst Naureen Quibria assigned a Buy rating on Immunocore Holdings (IMCR – Research Report) today and set a price target of...

Buy Rating on Immunocore Holdings Bolstered by KOL Insights and Oncology Advancements

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price ...

Immunocore Holdings (IMCR) Receives a Buy from Morgan Stanley

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

ALNY

AMGN

BMEZ

BPMC

CABA

CATX

CGEM

CGON

IDYA

IMCR

IOVA

ISRG

JANX

KURA

MRUS

NGNE

NONOF

NRIX

NUVL

RHHBF

RHHBY

RHHVF

SARTF

SILK

SOAGY

SSSGY

SUVPF

TSHA

UTHR

Press Releases

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Immunocore to present at the Jefferies Global Healthcare Conference

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Comments

Immunocore Hldgs

Immunocore Hldgs (IMCR) Opzioni

Immunocore Hldgs (NASDAQ:IMCR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO